FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $164 | +811.1% | 77,199 | +1962.5% | 0.01% | +600.0% |
| Q2 2023 | $18 | -14.3% | 3,743 | -0.6% | 0.00% | 0.0% |
| Q1 2023 | $21 | -44.7% | 3,764 | -0.3% | 0.00% | -50.0% |
| Q4 2022 | $38 | -100.0% | 3,777 | -16.8% | 0.00% | -50.0% |
| Q3 2022 | $102,000 | -28.2% | 4,542 | -20.8% | 0.00% | 0.0% |
| Q2 2022 | $142,000 | -36.0% | 5,732 | +0.2% | 0.00% | -20.0% |
| Q1 2022 | $222,000 | -42.2% | 5,723 | -12.9% | 0.01% | -37.5% |
| Q4 2021 | $384,000 | -0.8% | 6,571 | +0.6% | 0.01% | -11.1% |
| Q3 2021 | $387,000 | -34.6% | 6,535 | -4.2% | 0.01% | -18.2% |
| Q2 2021 | $592,000 | – | 6,825 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |